Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 44,084 shares of the biopharmaceutical company’s stock after purchasing an additional 409 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Regeneron Pharmaceuticals were worth $31,402,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Empowered Funds LLC boosted its position in shares of Regeneron Pharmaceuticals by 7.1% during the 3rd quarter. Empowered Funds LLC now owns 1,652 shares of the biopharmaceutical company’s stock valued at $1,737,000 after acquiring an additional 109 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Regeneron Pharmaceuticals by 16.7% during the 3rd quarter. Thrivent Financial for Lutherans now owns 9,120 shares of the biopharmaceutical company’s stock valued at $9,587,000 after acquiring an additional 1,306 shares during the last quarter. LMR Partners LLP acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $241,000. Prospera Financial Services Inc acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $778,000. Finally, Fifth Third Wealth Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 27.0% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 504 shares of the biopharmaceutical company’s stock valued at $530,000 after acquiring an additional 107 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $662.62 on Friday. The stock has a 50 day moving average price of $690.20 and a 200 day moving average price of $821.82. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $72.44 billion, a price-to-earnings ratio of 17.31, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $11.86 earnings per share. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Analysts Set New Price Targets

REGN has been the topic of several recent research reports. Bernstein Bank lowered their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, TD Cowen reduced their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.